Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-1.36
EPS est.
$-1.23
EPS surprise
-10.84%
1-day move
+4.16%
Despite missing revenue expectations, Arrowhead Pharmaceuticals reported a smaller-than-expected loss per share, which likely contributed to the positive stock reaction of 4.16%. Investors may have viewed the EPS surprise as a sign of better-than-anticipated operational performance. However, the lack of revenue and guidance updates leaves some uncertainty about future growth prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.36 | $-1.49 | +10.84% |
| Revenue | — | $64M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines that treat diseases caused by genetic mutations. With a market cap of $12 billion, it operates in the health care sector, which is increasingly important as advancements in gene therapy and personalized medicine gain traction.
Last quarter
In Q2-2026, Arrowhead reported an EPS of $-0.93, which was better than the expected $-1.18, resulting in a positive surprise of 20.85%. However, revenue figures were not disclosed, and the stock fell by 1.50% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
+514.67%
Avg 1-day reaction
+1.36%
Analysts expect Arrowhead to report a loss this quarter, with EPS estimates ranging from $-3.00 to $-0.62. Revenue expectations are more variable, indicating uncertainty about product uptake.
Bull case
If Arrowhead can exceed revenue expectations and narrow its EPS loss, it may indicate stronger demand for its therapies and improved operational efficiency, potentially boosting investor confidence.
Bear case
Conversely, if the company fails to meet revenue expectations or reports a wider loss than anticipated, it could raise concerns about the viability of its product pipeline and lead to a negative market reaction.
Key metrics to watch
EPS
$-1.49Earnings per share (EPS) is a key indicator of profitability and will show how well Arrowhead is managing its costs relative to its revenues.
Revenue
$64MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Arrowhead's revenue meet or exceed the consensus estimate of $64 million?
This figure will be crucial in assessing market demand for Arrowhead's therapies and could significantly influence investor sentiment.
Q2
Can the company narrow its EPS loss to improve investor confidence?
A smaller loss than expected could indicate better cost management and operational efficiency, which are vital for the company's future.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating Arrowhead's potential for revenue growth due to recent advancements in its product pipeline that have not been fully accounted for.
Supporting evidence
The company's recent positive EPS surprise indicates better-than-expected operational performance.
Options pricing suggests a significant move, indicating that traders expect a notable shift in sentiment post-earnings.
Key risk
If revenue comes in above $64 million, it could challenge the current bearish sentiment and shift expectations.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on Arrowhead's ability to demonstrate demand for its products and manage costs effectively.
Bull confirmed if
Revenue exceeding $64 million and an EPS loss narrower than $-1.49 would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-1.49 and revenue below $5 million would confirm the bear case.
What the market is pricing for the move.
Implied Move
±21.53%
Historical Avg
±3.8%
The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility based on the upcoming results.
Options are pricing ±21.5% while ARWR has averaged ±3.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
50.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Arrowhead beats expectations, history suggests the stock could rise by about 2.86% on the day, confirming positive market sentiment.
In line / cautious
If results come in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
If the company misses on both EPS and revenue, history suggests a potential decline of around 0.17%, reflecting investor disappointment.
The lines on the call that would change the story.